Epidermal Growth Factor Inhibitor-induced Cutaneous Toxicity Improves with Moisturizers

Ichiko Morino, Aika Okuno, Yuka Hirakawa, Yumiko Saya, Yumi Murakami, Fukumi Furukawa, Hiroshi Matsunaka

Article ID: 1187
Vol 4, Issue 2, 2020

VIEWS - 745 (Abstract) 384 (PDF)

Abstract


Although epidermal growth factor receptor (EGFR) inhibitors are one of the most effective treatment options for lung cancer, they frequently cause cutaneous toxicity that can lead to treatment discontinuation. Dryness, which is a common form of cutaneous toxicity, is usually treated using medical moisturizing agents. We aimed to investigate the treatment of cutaneous toxicity caused by EGFR inhibitors by comparing patients who used a cosmetic moisturizer with those who used conventional medical moisturizers. This study included 12 patients with lung cancer, who were receiving EGFR inhibitors and using topical medical moisturizers. The participants were assigned to a group that continued using medical moisturizers or a group that began using NOV® skin cream D. The study’s findings showed that like conventional medical moisturizers, NOV®skin cream D improved the cutaneous dryness caused by EGFR inhibitors and that it might additionally improve patients’ quality of life. Also, we obtained novel findings that NOV® skin cream D normalized keratinization, which is a component of normal skin cell differentiation impeded by EGFR inhibitors. Hence, the cosmetic moisturizer may help to prevent the discontinuation of EGFR inhibitors, thereby ensuring their continuous therapeutic effects.


Keywords


Cutaneous Toxicity; Epidermal Growth Factor Receptor Inhibitors; Moisturizer; Quality of Life; Stratum Corneum Water Content

Full Text:

PDF


References


1. Cufer T, Ovcaricek T, O'Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013; 49(6): 1216–1225. doi: 10.1016/j.ejca.2012.11.021.

2. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006; 11(9): 1010–1017. doi: 10.1634/theoncologist.11-9-1010.

3. Bianchini D, Jayanth A, Chua YJ, et al. Epidermal growth factor receptor inhibitor-related skin toxicity: Mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer 2008; 7(1): 33–43. doi: 10.3816/CCC.2008.n.005.

4. Orditura M, De Vita F, Galizia G, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: A single institution retrospective analysis. Oncol Rep 2009; 21(4): 1023–1028. doi: 10.3892/or_00000319.

5. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28(8): 1351–1357. doi: 10.1200/JCO.2008.21.7828.

6. Nakahara T, Moroi Y, Takayama K, et al. Physiological change in cutaneous toxicity related to epidermal growth factor receptor (EGFR) inhibitors and the efficacy of emollient. Nishinihon J Dermatology 2014; 76: 242–247.

7. Nakahara T, Moroi Y, Takayama K, et al. Effective supportive care for patients with different physiological changes in various skin regions induced by EGFR inhibitors. Nishinihon J Dermatology 2015; 77(4): 399–405. doi: 10.2336/nishinihonhifu.77.399.

8. Terui T, Hirao T, Sato Y, et al. An increased ratio of interleukin-1 receptor antagonist to interleukin-1alpha in inflammatory skin diseases. Exp Dermatol 1998; 7(6): 327–334.

9. Fukushima S, Morita E, Tanioka M, et al. Clinical evaluation of moisturizers with physiological analysis of stratum corneum TARC and TSLP. Journal of Cosmetics, Dermatological Sciences and Applications 2014; 4(1): 37–43. doi: 10.4236/jcdsa.2014.41006.

10. Redoules D, Tarroux R, Assalit MF, et al. Characterisation and assay of five enzymatic activities in the stratum corneum using tape-strippings. Skin Pharmacol Appl Skin Physiol 1999; 12(4): 182–192. doi: 10.1159/000066242.

11. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6(10): 803–812. doi: 10.1038/nrc1970.

12. Sano Y, Masuda K, Tamagawa-Mineoka R, et al. Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin Exp Immunol 2013; 171(3): 330–337. doi: 10.1111/cei.12021.

13. Nakahara T. Epidermal growth factor inhibitor-induced skin toxicity: Clinical symptoms, management, and mechanisms. Nishinihon J Dermatology 2015; 77(3): 203–209. doi: 10.2336/nishinihonhifu.77.203.




DOI: https://doi.org/10.24294/ti.v4.i2.1187

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Ichiko Morino, Aika Okuno, Yuka Hirakawa, Yumiko Saya, Yumi Murakami, Fukumi Furukawa, Hiroshi Matsunaka

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.